Nima Sharifi
Nima Sharifi
University of Miami Miller School of Medicine
Geverifieerd e-mailadres voor miami.edu - Homepage
Geciteerd door
Geciteerd door
Androgen deprivation therapy for prostate cancer
N Sharifi, JL Gulley, WL Dahut
Jama 294 (2), 238-244, 2005
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
KH Chang, R Li, M Papari-Zareei, L Watumull, YD Zhao, RJ Auchus, ...
Proceedings of the National Academy of Sciences 108 (33), 13728-13733, 2011
New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis
Y Hou, J Zhao, W Martin, A Kallianpur, MK Chung, L Jehi, N Sharifi, ...
BMC medicine 18 (1), 1-8, 2020
Androgen signaling in prostate cancer
C Dai, H Heemers, N Sharifi
Cold Spring Harbor perspectives in medicine 7 (9), 2017
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer
KH Chang, R Li, B Kuri, Y Lotan, CG Roehrborn, J Liu, R Vessella, ...
Cell 154 (5), 1074-1084, 2013
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Z Li, AC Bishop, M Alyamani, JA Garcia, R Dreicer, D Bunch, J Liu, ...
Nature 523 (7560), 347-351, 2015
Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer
A Hamada, T Sissung, DK Price, R Danesi, CH Chau, N Sharifi, D Venzon, ...
Clinical cancer research 14 (11), 3312-3318, 2008
An update on androgen deprivation therapy for prostate cancer
N Sharifi, JL Gulley, WL Dahut
Endocrine-related cancer 17 (4), R305-R315, 2010
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer
M Yang, W Xie, E Mostaghel, M Nakabayashi, L Werner, T Sun, ...
Journal of Clinical Oncology 29 (18), 2565, 2011
DNA-PKcs-mediated transcriptional regulation drives prostate cancer progression and metastasis
JF Goodwin, V Kothari, JM Drake, S Zhao, E Dylgjeri, JL Dean, ...
Cancer cell 28 (1), 97-113, 2015
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
Z Li, M Alyamani, J Li, K Rogacki, M Abazeed, SK Upadhyay, SP Balk, ...
Nature 533 (7604), 547-551, 2016
A retrospective study of the time to clinical endpoints for advanced prostate cancer
N Sharifi, WL Dahut, SM Steinberg, WD Figg, C Tarassoff, P Arlen, ...
BJU international 96 (7), 985-989, 2005
Steroid biosynthesis and prostate cancer
N Sharifi, RJ Auchus
Steroids 77 (7), 719-726, 2012
Hormonal therapy for prostate cancer
K Desai, JM McManus, N Sharifi
Endocrine reviews 42 (3), 354-373, 2021
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study
JWD Hearn, G AbuAli, CA Reichard, CA Reddy, C Magi-Galluzzi, ...
The Lancet Oncology 17 (10), 1435-1444, 2016
Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer
R Li, K Evaul, KK Sharma, KH Chang, J Yoshimoto, J Liu, RJ Auchus, ...
Clinical cancer research 18 (13), 3571-3579, 2012
Mechanisms of androgen receptor activation in castration-resistant prostate cancer
N Sharifi
Endocrinology 154 (11), 4010-4017, 2013
Molecular pathways: inhibiting steroid biosynthesis in prostate cancer
R Ferraldeschi, N Sharifi, RJ Auchus, G Attard
Clinical cancer research 19 (13), 3353-3359, 2013
Generation of dynorphin knockout mice
N Sharifi, N Diehl, L Yaswen, MB Brennan, U Hochgeschwender
Molecular brain research 86 (1-2), 70-75, 2001
Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer
J Li, M Alyamani, A Zhang, KH Chang, M Berk, Z Li, Z Zhu, M Petro, ...
Elife 6, e20183, 2017
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20